A role for IL-1 inhibitors in the treatment of non-alcoholic fatty liver disease (NAFLD)?

References

• Mantovani A, Dinarello CA, Molgora M, et al. Interleukin-1 and related cytokines in the regulation of inflammation and immunity. Immunity. 2019 Apr 16;50(4):778–795. PubMed PMID: 30995499. Epub 2019/04/18.
   PubMed Web of Science ®Google Scholar
• Hoffman HM, Mueller JL, Broide DH, et al. Mutation of a new gene encoding a putative pyrin-like protein causes familial cold autoinflammatory syndrome and muckle-wells syndrome. Nat Genet. 2001 Nov;29(3):301–305. PubMed PMID: 11687797. Pubmed Central PMCID: PMC4322000. Epub 2001 11 01.
   PubMed Web of Science ®Google Scholar
• Netea MG, Balkwill F, Chonchol M, et al. A guiding map for inflammation. Nat Immunol. 2017 Jul 19;18(8):826–831. PubMed PMID: 28722720. Pubmed Central PMCID: 5939996.
   PubMed Web of Science ®Google Scholar
• Diehl AM, Day C. Cause, pathogenesis, and treatment of nonalcoholic steatohepatitis. N Engl J Med. 2017 Nov 23;377(21):2063–2072. PubMed PMID: 29166236. Epub 2017 11 23.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR, Szabo G. Interleukin-1 and inflammasomes in alcoholic liver disease/acute alcoholic hepatitis and nonalcoholic fatty liver disease/nonalcoholic steatohepatitis. Hepatology. 2016 Sep;64(3):955–965. PubMed PMID: 26773297.
   PubMed Web of Science ®Google Scholar
• Tilg H, Moschen AR. Evolution of inflammation in nonalcoholic fatty liver disease: the multiple parallel hits hypothesis. Hepatology. 2010 Nov;52(5):1836–1846. PubMed PMID: 21038418.
   PubMed Web of Science ®Google Scholar
• Tilg H, Zmora N, Adolph TE, et al. The intestinal microbiota fuelling metabolic inflammation. Nat Rev Immunol. 2019 Aug 6. PubMed PMID: 31388093.
   PubMedGoogle Scholar
• Pihlajamaki J, Kuulasmaa T, Kaminska D, et al. Serum interleukin 1 receptor antagonist as an independent marker of non-alcoholic steatohepatitis in humans. J Hepatol. 2012 Mar;56(3):663–670. PubMed PMID: 22027586.
   PubMed Web of Science ®Google Scholar
• Kamari Y, Shaish A, Vax E, et al. Lack of interleukin-1alpha or interleukin-1beta inhibits transformation of steatosis to steatohepatitis and liver fibrosis in hypercholesterolemic mice. J Hepatol. 2011 Nov;55(5):1086–1094. PubMed PMID: 21354232. Pubmed Central PMCID: PMC3210940. Epub 2011/03/01.
   PubMed Web of Science ®Google Scholar
• Dixon LJ, Flask CA, Papouchado BG, et al. Caspase-1 as a central regulator of high fat diet-induced non-alcoholic steatohepatitis. PLoS One. 2013;8(2):e56100. PubMed PMID: 23409132. Pubmed Central PMCID: PMC3567081. Epub 2013 02 15.
   PubMed Web of Science ®Google Scholar
• Gao Y, Liu Y, Yang M, et al. IL-33 treatment attenuated diet-induced hepatic steatosis but aggravated hepatic fibrosis. Oncotarget. 2016 Jun;7;7(23):33649–33661. PubMed PMID: 27172901. Pubmed Central PMCID: PMC5085109. Epub 2016 05 14.
   Google Scholar
• Vasseur P, Dion S, Filliol A, et al. Endogenous IL-33 has no effect on the progression of fibrosis during experimental steatohepatitis. Oncotarget. 2017 Jul 25;8(30):48563–48574. PubMed PMID: 28611297. Pubmed Central PMCID: PMC5564708. Epub 2017/06/15.
   PubMedGoogle Scholar
• Cazanave S, Podtelezhnikov A, Jensen K, et al. The transcriptomic signature of disease development and progression of nonalcoholic fatty liver disease. Sci Rep. 2017 Dec 8;7(1):17193. PubMed PMID: 29222421. Pubmed Central PMCID: PMC5722878. Epub 2017/12/10.
   PubMedGoogle Scholar
• Yamanishi K, Maeda S, Kuwahara-Otani S, et al. Interleukin-18-deficient mice develop dyslipidemia resulting in nonalcoholic fatty liver disease and steatohepatitis. Transl Res. 2016 Jul;173:101–14 e7. PubMed PMID: 27063959. Epub 2016/04/12.
   PubMed Web of Science ®Google Scholar
• Stienstra R, Joosten LA, Koenen T, et al. The inflammasome-mediated caspase-1 activation controls adipocyte differentiation and insulin sensitivity. Cell Metab. 2010 Dec 1;12(6):593–605. PubMed PMID: 21109192. Pubmed Central PMCID: PMC3683568. Epub 2010/11/27.
   PubMed Web of Science ®Google Scholar
• He J, Usui I, Ishizuka K, et al. Interleukin-1alpha inhibits insulin signaling with phosphorylating insulin receptor substrate-1 on serine residues in 3T3-L1 adipocytes. Mol Endocrinol. 2006 Jan;20(1):114–124. PubMed PMID: 16150868. Epub 2005/ 09/10.
   PubMedGoogle Scholar
• Ballak DB, van Diepen JA, Moschen AR, et al. IL-37 protects against obesity-induced inflammation and insulin resistance. Nat Commun. 2014;5:4711. PubMed PMID: 25182023.
   PubMed Web of Science ®Google Scholar
• Moschen AR, Molnar C, Enrich B, et al. Adipose and liver expression of interleukin (IL)-1 family members in morbid obesity and effects of weight loss. Mol Med. 2011;17(7–8):840–845. PubMed PMID: 21394384. Pubmed Central PMCID: 3146615.
   PubMed Web of Science ®Google Scholar
• Larsen CM, Faulenbach M, Vaag A, et al. Interleukin-1-receptor antagonist in type 2 diabetes mellitus. N Engl J Med. 2007 Apr 12;356(15):1517–1526. PubMed PMID: 17429083.
   PubMed Web of Science ®Google Scholar
• Hung AM, Limkunakul C, Placido JS, et al. Administration of IL-1ra improves adiponectin levels in chronic hemodialysis patients. J Nephrol. 2014 Dec;27(6):681–688. PubMed PMID: 24609887. Epub 2014/03/13.
   PubMed Web of Science ®Google Scholar
• Vandanmagsar B, Youm YH, Ravussin A, et al. The NLRP3 inflammasome instigates obesity-induced inflammation and insulin resistance. Nat Med. 2011 Feb;17(2):179–188. PubMed PMID: 21217695. Pubmed Central PMCID: PMC3076025. Epub 2011/01/11.
   PubMed Web of Science ®Google Scholar
• Mridha AR, Wree A, Robertson AAB, et al. NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice. J Hepatol. 2017 May;66(5):1037–1046. PubMed PMID: 28167322. Pubmed Central PMCID: PMC6536116. Epub 2017/02/09.
   PubMed Web of Science ®Google Scholar
• Cai C, Zhu X, Li P, et al. NLRP3 deletion inhibits the non-alcoholic steatohepatitis development and inflammation in kupffer cells induced by palmitic acid. Inflammation. 2017 Dec;40(6):1875–1883. PubMed PMID: 28730512. Epub 2017/07/22.
   PubMed Web of Science ®Google Scholar
• Dror E, Dalmas E, Meier DT, et al. Postprandial macrophage-derived IL-1beta stimulates insulin, and both synergistically promote glucose disposal and inflammation. Nat Immunol. 2017 Mar;18(3):283–292. PubMed PMID: 28092375. Epub 2017/01/17.
   PubMed Web of Science ®Google Scholar
• Hojen JF, Kristensen MLV, McKee AS, et al. IL-1R3 blockade broadly attenuates the functions of six members of the IL-1 family, revealing their contribution to models of disease. Nat Immunol. 2019 Sep;20(9):1138–1149. PubMed PMID: 31427775. Pubmed Central PMCID: PMC6707854. Epub 2019/08/21.
   PubMed Web of Science ®Google Scholar
• Ridker PM, Everett BM, Thuren T, et al. Antiinflammatory therapy with canakinumab for atherosclerotic disease. N Engl J Med. 2017 Sep 21;377(12):1119–1131. PubMed PMID: 28845751.
   PubMed Web of Science ®Google Scholar
• Everett BM, Donath MY, Pradhan AD, et al. Anti-inflammatory therapy with canakinumab for the prevention and management of diabetes. J Am Coll Cardiol. 2018 May 29;71(21):2392–2401. PubMed PMID: 29544870.
   PubMed Web of Science ®Google Scholar